Cervical Intraepithelial Neoplasia (CIN) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Cervical Intraepithelial Neoplasia (CIN) – Pipeline Review, H2 2016’, provides an overview of the Cervical Intraepithelial Neoplasia (CIN) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cervical Intraepithelial Neoplasia (CIN), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cervical Intraepithelial Neoplasia (CIN) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Cervical Intraepithelial Neoplasia (CIN)

The report reviews pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Cervical Intraepithelial Neoplasia (CIN) therapeutics and enlists all their major and minor projects

The report assesses Cervical Intraepithelial Neoplasia (CIN) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Cervical Intraepithelial Neoplasia (CIN)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Cervical Intraepithelial Neoplasia (CIN)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cervical Intraepithelial Neoplasia (CIN) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

CEL-SCI Corp

Genexine Inc

Inovio Pharmaceuticals Inc

PDS Biotechnology Corp

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Transgene SA

Vaccibody AS

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Cervical Intraepithelial Neoplasia (CIN) Overview 7

Therapeutics Development 8

Pipeline Products for Cervical Intraepithelial Neoplasia (CIN) - Overview 8

Pipeline Products for Cervical Intraepithelial Neoplasia (CIN) - Comparative Analysis 9

Cervical Intraepithelial Neoplasia (CIN) - Therapeutics under Development by Companies 10

Cervical Intraepithelial Neoplasia (CIN) - Therapeutics under Investigation by Universities/Institutes 11

Cervical Intraepithelial Neoplasia (CIN) - Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Cervical Intraepithelial Neoplasia (CIN) - Products under Development by Companies 14

Cervical Intraepithelial Neoplasia (CIN) - Products under Investigation by Universities/Institutes 15

Cervical Intraepithelial Neoplasia (CIN) - Companies Involved in Therapeutics Development 16

CEL-SCI Corp 16

Genexine Inc 17

Inovio Pharmaceuticals Inc 18

PDS Biotechnology Corp 19

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd 20

Transgene SA 21

Vaccibody AS 22

Cervical Intraepithelial Neoplasia (CIN) - Therapeutics Assessment 23

Assessment by Monotherapy Products 23

Assessment by Target 24

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Drug Profiles 30

ABI-1968 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

aminolevulinic acid hydrochloride - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

DNA Vaccine to Target E7 for HPV Associated Cancers - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

DNA Vaccine to Target E7 for HPV Associated Cervical Intraepithelial Neoplasia - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

GLBL-101c - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

GX-188E - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Leukocyte Interleukin - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

PDS-0101 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

TG-4001 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Vaccine for Cervical Intraepithelial Neoplasia - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

VB-1016 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

VGX-3100 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

Cervical Intraepithelial Neoplasia (CIN) - Dormant Projects 60

Cervical Intraepithelial Neoplasia (CIN) - Discontinued Products 61

Cervical Intraepithelial Neoplasia (CIN) - Product Development Milestones 62

Featured News & Press Releases 62

Oct 24, 2016: Inovio Announces FDA Request for Additional Information For Phase III Program; Trial Initiation Delayed 62

Jun 21, 2016: Genexine Presents Interim Clinical Data of GX-188E at EUROGIN 2016 62

Mar 30, 2016: Inovio Pharmaceuticals HPV Immunotherapy Selected as “Best Therapeutic Vaccine” by World Vaccine Congress 63

Sep 17, 2015: Inovio Pharmaceuticals Publishes Successful Phase 2b Trial Results of Its HPV Immunotherapy in The Lancet 63

Apr 23, 2015: Global clinical development accelerated as cervical intraepithelial neoplasia therapeutic, GX-188E received expanded approval for Phase II from Europe 65

Mar 02, 2015: Genexines cervical intraepithelial neoplasia therapeutic "GX-188E" receives approval for Phase II in Europe 65

Jul 23, 2014: Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 66

Jun 11, 2014: Inovio Pharmaceuticals Clarifies Facts of its VGX-3100 Phase II Trial and Immunotherapy Technology 67

Oct 10, 2012: Inovio Pharma's DNA-based Therapeutic Cancer Vaccine Produces Immune Responses To Kill Target Cells In Phase I Study 68

May 01, 2012: Inovio Receives US Patent Protection For Synthetic Vaccine For Cervical Dysplasia And Cancer 69

Oct 31, 2011: Fierce Vaccines Highlights Inovio's Cervical Dysplasia And Cancer Vaccine As One Of 10 Promising Therapeutic Vaccines 70

Oct 05, 2011: Inovio's Synthetic Vaccine For Cancer Recognized As Most Promising Research At Global Vaccine Congress 71

Jul 15, 2011: Inovio Demonstrates T Cell Immune Response From Therapeutic Cervical Dysplasia And Cancer DNA Vaccine 71

May 09, 2011: Inovio Reports Long-Term Immune Responses From Therapeutic Cervical Dysplasia And Cancer DNA Vaccine 72

Appendix 74

Methodology 74

Coverage 74

Secondary Research 74

Primary Research 74

Expert Panel Validation 74

Contact Us 74

Disclaimer 75

List of Tables

List of Tables

Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), H2 2016 8

Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN) – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Cervical Intraepithelial Neoplasia (CIN) – Pipeline by CEL-SCI Corp, H2 2016 16

Cervical Intraepithelial Neoplasia (CIN) – Pipeline by Genexine Inc, H2 2016 17

Cervical Intraepithelial Neoplasia (CIN) – Pipeline by Inovio Pharmaceuticals Inc, H2 2016 18

Cervical Intraepithelial Neoplasia (CIN) – Pipeline by PDS Biotechnology Corp, H2 2016 19

Cervical Intraepithelial Neoplasia (CIN) – Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2016 20

Cervical Intraepithelial Neoplasia (CIN) – Pipeline by Transgene SA, H2 2016 21

Cervical Intraepithelial Neoplasia (CIN) – Pipeline by Vaccibody AS, H2 2016 22

Assessment by Monotherapy Products, H2 2016 23

Number of Products by Stage and Target, H2 2016 25

Number of Products by Stage and Route of Administration, H2 2016 27

Number of Products by Stage and Molecule Type, H2 2016 29

Cervical Intraepithelial Neoplasia (CIN) – Dormant Projects, H2 2016 60

Cervical Intraepithelial Neoplasia (CIN) – Discontinued Products, H2 2016 61

List of Figures

List of Figures

Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN), H2 2016 8

Number of Products under Development for Cervical Intraepithelial Neoplasia (CIN) – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 12

Assessment by Monotherapy Products, H2 2016 23

Number of Products by Targets, H2 2016 24

Number of Products by Stage and Targets, H2 2016 24

Number of Products by Routes of Administration, H2 2016 26

Number of Products by Stage and Routes of Administration, H2 2016 26

Number of Products by Molecule Types, H2 2016 28

Number of Products by Stage and Molecule Types, H2 2016 28

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports